Akebia Therapeutics

March is National Kidney Month. Team Akebia recognizes the strength of people impacted by kidney disease and the unwavering dedication of caregivers. Together we support greater awareness and understanding of kidney disease. #NationalKidneyMonth #KidneyHealth

PRESS RELEASE: Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights: ir.akebia.com/news-releases/…

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS): Link: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Announces Establishment of Rare Kidney Disease Pipeline. View details here: ir.akebia.com/news-releases/…

More than 550,000 Americans with chronic kidney disease are on dialysis. We welcomed @NKFNewEngland and joined the Drive for Dialysis, an initiative to help ease the burden of dialysis. Care packages are headed to a local dialysis center to support patients in our community.

Thank you to @ASNKidney for a productive #KidneyWk 2025. We left Houston energized and with renewed commitment to work together to better the lives of people impacted by kidney disease.

Akebia Therapeutics announced results from a new post hoc analysis from clinical studies. The analysis evaluated a composite of all-cause mortality and hospitalization outcomes in dialysis-dependent patients. Read the full press release here: tinyurl.com/38kr4ydf

PRESS RELEASE: Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights: ir.akebia.com/news-releases/…

It’s been a great start to #KidneyWk! Akebia experts are at Booth #903 and discussing our latest research in chronic kidney disease. Be sure to visit and learn about our scientific explorations!

At @ASNKidney Kidney Week 2025? Stop by to see representatives from Akebia in the Poster Hall. We're eager to connect with the Nephrology Community!

@ASNKidney Kidney Week attendees: Visit the poster gallery on November 7 at 10:00 AM CT to view Poster INFO10, highlighting the VOCAL study design – evaluating TIW dosing of an oral HIF-PHI for the treatment of CKD-related anemia in adults on dialysis: asn-online.org/education/kidn…

Healthcare professionals @ASNKidney #KidneyWk: Dr. Geoffrey Block at U.S. Renal Care will showcase the VOICE study design - a trial evaluating the safety of a new anemia management strategy. View Poster #204 on November 7 at 10:00 AM CT: asn-online.org/education/kidn…

HCPs: Join Dr. Glenn Chertow at @ASNKidney #KidneyWk as he presents win-odds analysis of the INNO2VATE study. Dr. Chertow presents at 4:40 PM CT in room 315D: asn-online.org/education/kidn…

Are you attending @ASNKidney #KidneyWk? Visit the poster hall on November 6 at 10:00 AM CT. Poster #902 displays model-based dosing data for an oral HIF-PHI as a treatment of anemia in dialysis-dependent CKD patients.

We’re on the ground in Houston for @ASNKidney #KidneyWk. Plan to visit Akebia's Commercial and Medical Affairs Teams at Booth #903 and check out the latest data on display in the poster hall: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics to Present at Upcoming Investor Conferences: ir.akebia.com/news-releases/…